Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Tekcapital LSE:TEK London Ordinary Share GB00BKXGY798 ORD £0.004
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 6.50p 6.00p 7.00p 6.50p 6.50p 6.50p 18,010 05:00:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Technology Hardware & Equipment 5.4 3.1 8.0 0.8 3.53

Tekcapital Share Discussion Threads

Showing 451 to 475 of 475 messages
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
DateSubjectAuthorDiscuss
17/1/2019
17:21
1 share buy of 20k volume sends the share price north by 4% What’s not to like about that. Nice and as I have previously stated, could be a “star” of 2019
29palms
11/1/2019
16:03
not sure reading Align's research really adds much. Not really independent and they've receommended some dogs in the past.
lardarse69
07/1/2019
18:55
Upward momentum since hitting 52 week low on the week running up to Christmas has been impressive. As previously stated this could be a "star" of 2019
29palms
05/1/2019
10:30
Well worth a read over the weekend. Full report update from 3rd October here- http://www.alignresearch.co.uk/wp-content/uploads/2018/10/Tekcapital_Update_Align_Research_3rd_October_2018.pdf Stand out for me is value placed on investee company Salarius "rising from $15,128 to $2 million following an external valuation"
29palms
04/1/2019
16:01
...as I have stated previously this could be a "star" of 2019 As always, DYOR
29palms
04/1/2019
10:27
Nice move up today, undervalued IMO As always, DYOR
29palms
03/1/2019
09:43
Thanks for posting the link. Basically programmed questions which Gross replies to by reading from a script. Impressive!! Off course what he doesn't mention that is they have yet to attract one partner for any of their technology and are now faced with having to develop, market and sell these divisions themselves. That is not going to be cheap is it? Salarius is really disappointing, why have all the big boys walked away? One problem being that we do not know what else is out there, may be something better who knows? Previous hyped up crackle bake doesn't even get mentioned. I wonder why? But relax. He's very exciting about TEK in 2019, just as he has been for every other year. I'm amazed he's kept his position.
pj 1
03/1/2019
07:48
http://www.alignresearch.co.uk/tekcapital/zak-mir-interviews-clifford-gross-of-tekcapital-2/
richie666
28/12/2018
16:40
Luv your dual posting, here on ADVFN and on LSE Good on you for getting the message out!! Very undervalued even after today’s healthy rise. A star for 2019 I would say.
29palms
28/12/2018
16:33
http://www.alignresearch.co.uk/powerhouse-energy/align-research-top-10-picks-2019/ 9. Tek Capital – current price 4.8p We provided a recent full update on Tek Capital per HERE on 3 October 2018. Our stance here is pretty simple – with a market cap of just over £2.5m set against a stated NAV of @ £8.6m this disjoint is too large. Each of the constituent business offer real growth potential but the real “jewel in the crown” to us is Belluscura the medical devices business. The key product within Belluscura is CURV™ – a portable oxygen concentrator (POC) and where the market is expected to nearly double to $2.2bn in the next 2 years. The company’s prototype POC is quiet unlike its competitors and once developed is expected to be also lower cost than the competition. Belluscura plans to file a 510(K) imminently and we expect this to be a catalyst to a re-rating by the market as the commercial implications thereof become apparent. We would not be surprised at some point during 2019 if Belluscura receives investment that values Tek’s 29% stake at a premium to the total current market capitalisation and a wholesale exit be on the horizon as market traction is gained into 2020 for CURV. Such an exit could be multiples of the current TEK stock price. The other key business within Tek’s portfolio that we really like is Salarius the low sodium salt product (Microsalt) – the market opportunities her really are material with the Salarius product boasting c.67% less sodium by weight than standard table salt due to its smaller size and claiming to be the world’s smallest salt crystal. The product meets a growing need for the reduction of sodium in salt containing products, driven by negative health effects that excess sodium consumption can cause. Salarius is currently looking to out license its patented product and news here could also be a value driver for the stock. Further, based on the most recent investment into Salarius, fully in excess of 3p of the current stock price is accounted for by this business alone. At a price of 4.9p and trading at a significant discount to peers Allied Minds and IP Group, the shares currently offer a very deep discount to NAV with, importantly, management holding a large stake and so focused and incentivised to crystallise value within the portfolio. The shares can be purchased at a further discount to the recent placing at 7p and we expect to see a doubling and beyond in the stock price as value catalysts occur in 2019. Buy.
richie666
28/12/2018
16:11
Nice move north today from 52 week low and could be a ‘star’ of 2019 As always - DYOR
29palms
28/12/2018
11:36
One of their best investee companies for me is Salarius TEK owns 97.5% As always - DYOR
29palms
28/12/2018
11:23
Unless you want a pair of talking spectacles then I'd suggest currently their NAV is not far off zero. Cackle bake at least needs to be written down as it appears to have ''died'' a death!
pj 1
28/12/2018
11:11
These might be worth a look, i'm undecided. After the recent fundraise the cash in the bank can't be that far off the market cap, but having looked at their investee companies i'm not sure I think the stated NAV is realistic at this time and hence the large discount may be warranted.
arthur_lame_stocks
28/12/2018
11:04
Align research update - worth a read http://www.alignresearch.co.uk/cpt-company/tekcapital/
29palms
22/11/2018
13:58
Here is the chance to meet with Tekcapital: Using this unique discount code, ADVFN25, you will be able to get £25 off at Mello London 2018, a 2 day investor conference from the 26th – 27th November 2018 at the Clayton Hotel, Chiswick, London. Http://melloevents.com/mello-london/ Tickets are normally priced at £99 for two days and £79 for one. Type in ADVFN25 as the discount code. Many Thanks and take advantage of this premium offer.
advfn_sales
07/9/2018
08:20
Possibly but for what as they have cash
battlebus2
07/9/2018
08:11
placing on the way?
eentweedrie
04/9/2018
15:30
Held for many a year and have only made through the several trades I’ve made. I’m always hopeful but not banking on it. Small holding only.
battlebus2
04/9/2018
15:19
Thanks guys. battlebus24 Sep '18 - 16:02 - 432 of 432 0 0 0 We live in hope PJ 🤨 Not one of your bankers then BB!
tiswas
04/9/2018
15:02
We live in hope PJ 🤨
battlebus2
04/9/2018
13:47
Yes I've only just entered at recent levels. Am less familiar with history about what was said when but share offers a great value entry. Salarius -must be gearing up for a deal. Big hitters hired with relevant multinational and product experience (Pringles). Belluscura- Portable oxygen concentrator that appears to offer a USP compared to the market leader product. Waiting for it's FDA approval to be submitted. Expecting another attempt at IPO beyond that. Lucyd- developing augmented reality glasses fully financed via unique token offering.
toadhall1
04/9/2018
13:35
lol Its been hit because they have yet to sign any of the promised monetary deal with any of the IP they have. They also listed Belluscura in an underhanded manner without stating a change of strategy. Align research is paid for by the Company. Gross gave an 18 month timeline before major deals were announced. To date zilch. Off course one could land tomorrow, that's the gamble.
pj 1
04/9/2018
13:29
Believe this to be great value entry. It's mainly been hit by overselling, most recently Legal and General. Please see below report. It's on the website. When this was written share price was 18p. Since then there have also been key hires in the Salarius investee company. https://www.tekcapital.com/wp-content/uploads/2018/05/Tekcapital_Align_Reseach_FY_Update_8th_May_2018.pdf
toadhall1
04/9/2018
10:46
Net asset per share at 31 May 2018: US$0.25 (H1 2017: US$0.19). So the share price is at a 50% discount to nav? I guess this is normal for a portfolio of unquoted investments but does anyone have any broker research they can share on the portfolio as this is the first time it has come to my attention? Thanks
tiswas
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
Your Recent History
LSE
TEK
Tekcapital
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190119 23:24:22